[[The ultrathin-strut everolimus-eluting stent in a real-world population: the Everythin multicenter registry]].

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
REC Interventional Cardiology Pub Date : 2025-02-24 eCollection Date: 2025-01-01 DOI:10.24875/RECIC.M24000484
Juan Casanova-Sandoval, Gema Miñana-Escrivà, Eduard Bosch-Peligero, Juan Francisco Muñoz-Camacho, Diego Fernández-Rodríguez, Kristian Rivera, Agustín Fernández-Cisnal, Daniel Valcárcel-Paz, Marcos García-Guimarães
{"title":"[[The ultrathin-strut everolimus-eluting stent in a real-world population: the Everythin multicenter registry]].","authors":"Juan Casanova-Sandoval, Gema Miñana-Escrivà, Eduard Bosch-Peligero, Juan Francisco Muñoz-Camacho, Diego Fernández-Rodríguez, Kristian Rivera, Agustín Fernández-Cisnal, Daniel Valcárcel-Paz, Marcos García-Guimarães","doi":"10.24875/RECIC.M24000484","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Ultrathin-strut stents (UTS) represent a significant advancement in percutaneous coronary intervention. This study aimed to evaluate the safety and short- to mid-term outcomes of stenting with the thinnest struts on the market (50 µm) using a biodegradable everolimus-eluting polymer (Evermine 50) in real-world patients with coronary artery disease.</p><p><strong>Methods: </strong>A single-arm, multicenter, prospective study was conducted in real-world patients. A total of 161 patients with de novo lesions who received at least 1 UTS stent were enrolled. The primary safety endpoint was the occurrence of major adverse cardiovascular events, defined as cardiac death, target-vessel myocardial infarction, or the need for revascularization of the target lesion at 12 months. The incidence of stent thrombosis at 12 months was also analyzed.</p><p><strong>Results: </strong>The study included 161 patients with a mean age of 64 ± 14 years; 79% were male, 34% had diabetes, and 66% had hypertension. The most common indication for intervention was non-ST-segment elevation myocardial infarction (42%), followed by ST-segment elevation myocardial infarction (22%). The procedural success rate was 100%. At 12 months of follow-up, the incidence of MACE was 2.5%, and the definite stent thrombosis rate was 1.3%.</p><p><strong>Conclusions: </strong>The use of the 50 µm UTS stent with a biodegradable everolimus-eluting polymer demonstrated a favorable safety profile and good clinical outcomes in unselected patients at 1 year of follow-up.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"7 1","pages":"23-28"},"PeriodicalIF":1.2000,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097315/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"REC Interventional Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24875/RECIC.M24000484","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and objectives: Ultrathin-strut stents (UTS) represent a significant advancement in percutaneous coronary intervention. This study aimed to evaluate the safety and short- to mid-term outcomes of stenting with the thinnest struts on the market (50 µm) using a biodegradable everolimus-eluting polymer (Evermine 50) in real-world patients with coronary artery disease.

Methods: A single-arm, multicenter, prospective study was conducted in real-world patients. A total of 161 patients with de novo lesions who received at least 1 UTS stent were enrolled. The primary safety endpoint was the occurrence of major adverse cardiovascular events, defined as cardiac death, target-vessel myocardial infarction, or the need for revascularization of the target lesion at 12 months. The incidence of stent thrombosis at 12 months was also analyzed.

Results: The study included 161 patients with a mean age of 64 ± 14 years; 79% were male, 34% had diabetes, and 66% had hypertension. The most common indication for intervention was non-ST-segment elevation myocardial infarction (42%), followed by ST-segment elevation myocardial infarction (22%). The procedural success rate was 100%. At 12 months of follow-up, the incidence of MACE was 2.5%, and the definite stent thrombosis rate was 1.3%.

Conclusions: The use of the 50 µm UTS stent with a biodegradable everolimus-eluting polymer demonstrated a favorable safety profile and good clinical outcomes in unselected patients at 1 year of follow-up.

超薄支架依维莫司洗脱支架在真实人群中的应用:Everythin多中心注册研究[j]。
简介和目的:超薄支架(UTS)代表了经皮冠状动脉介入治疗的重大进展。本研究旨在评估市场上最薄支撑物(50µm)使用可生物降解依维莫昔洗脱聚合物(Evermine 50)在现实世界冠状动脉疾病患者中的安全性和中短期结果。方法:在真实世界的患者中进行单臂、多中心、前瞻性研究。共有161例接受至少1个UTS支架的新发病变患者被纳入研究。主要安全性终点是主要不良心血管事件的发生,定义为心源性死亡、靶血管心肌梗死或12个月时靶病变需要血运重建。分析12个月支架内血栓的发生率。结果:纳入161例患者,平均年龄64±14岁;79%为男性,34%为糖尿病患者,66%为高血压患者。最常见的干预指征是非st段抬高型心肌梗死(42%),其次是st段抬高型心肌梗死(22%)。手术成功率100%。随访12个月时,MACE发生率为2.5%,明确支架血栓形成率为1.3%。结论:在未选择的1年随访患者中,使用带有可生物降解依维莫司洗脱聚合物的50µm UTS支架具有良好的安全性和良好的临床结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
REC Interventional Cardiology
REC Interventional Cardiology Medicine-Cardiology and Cardiovascular Medicine
CiteScore
3.10
自引率
28.60%
发文量
87
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信